CR20200124A - Inhibidores macrocíclicos de mcl-1 y métodos de uso - Google Patents

Inhibidores macrocíclicos de mcl-1 y métodos de uso

Info

Publication number
CR20200124A
CR20200124A CR20200124A CR20200124A CR20200124A CR 20200124 A CR20200124 A CR 20200124A CR 20200124 A CR20200124 A CR 20200124A CR 20200124 A CR20200124 A CR 20200124A CR 20200124 A CR20200124 A CR 20200124A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
methods
mcl
macrocyclic
compounds
Prior art date
Application number
CR20200124A
Other languages
English (en)
Inventor
Wilfried Braje
Andrew Souers
Gerard Sullivan
Michael Wendt
Thomas Penning
Andrew Judd
Cheng Ji
Xiaohong Song
Zhi-Fu Tao
Anthony Mastracchio
Jesse Teske
Katja Jantos
Aaron Kunzer
Frauke Pohlki
George Doherty
Chunqiu Lai
Xilu Wang
Andreas Kling
Original Assignee
Abbvie Inc
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Abbvie Deutschland filed Critical Abbvie Inc
Publication of CR20200124A publication Critical patent/CR20200124A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente divulgación proporciona compuestos de la Fórmula (I), en donde A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X e Y tienen cualquiera de los valores definidos en la memoria descriptiva, y sales aceptables desde el punto de vista farmacéutico de estos, que son útiles como agentes en el tratamiento de enfermedades y afecciones, incluido el cáncer. También se proporcionan composiciones farmacéuticas que comprenden compuestos de la Fórmula (I).
CR20200124A 2017-08-15 2018-08-15 Inhibidores macrocíclicos de mcl-1 y métodos de uso CR20200124A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762545853P 2017-08-15 2017-08-15
US201762555475P 2017-09-07 2017-09-07
US201862692663P 2018-06-30 2018-06-30
PCT/US2018/000180 WO2019035911A1 (en) 2017-08-15 2018-08-15 MACROCYCLIC INHIBITORS OF MCL-1 AND METHODS OF USE

Publications (1)

Publication Number Publication Date
CR20200124A true CR20200124A (es) 2020-09-28

Family

ID=65362347

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200124A CR20200124A (es) 2017-08-15 2018-08-15 Inhibidores macrocíclicos de mcl-1 y métodos de uso

Country Status (21)

Country Link
US (3) US10676485B2 (es)
EP (2) EP3988555A1 (es)
JP (1) JP2020531433A (es)
KR (1) KR20200041942A (es)
CN (1) CN111818917A (es)
AU (1) AU2018316620A1 (es)
BR (1) BR112020003180A2 (es)
CA (1) CA3073112A1 (es)
CL (2) CL2020000363A1 (es)
CO (1) CO2020002678A2 (es)
CR (1) CR20200124A (es)
EC (1) ECSP20018703A (es)
IL (1) IL272681A (es)
MX (1) MX2020001717A (es)
PH (1) PH12020500327A1 (es)
RU (1) RU2020110517A (es)
SG (2) SG10202106345VA (es)
TW (1) TW201920194A (es)
UA (1) UA126586C2 (es)
UY (1) UY37843A (es)
WO (1) WO2019035911A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364240B2 (en) 2017-08-15 2022-06-21 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders
WO2019035911A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. MACROCYCLIC INHIBITORS OF MCL-1 AND METHODS OF USE
CA3073114A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. Macrocyclic mcl-1 inhibitors and methods of use
US20190055264A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. Macrocyclic MCL-1 inhibitors and methods of use
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
CN111093663A (zh) 2017-09-07 2020-05-01 奥古斯塔大学研究所公司 特异性akt3激活剂及其用途
TW202100184A (zh) 2019-05-20 2021-01-01 瑞士商諾華公司 Mcl-1抑制劑抗體－藥物結合物及使用方法
CN117136076A (zh) 2020-11-24 2023-11-28 诺华股份有限公司 Mcl-1抑制剂抗体药物缀合物和使用方法
KR20240019330A (ko) 2021-06-11 2024-02-14 길리애드 사이언시즈, 인코포레이티드 Mcl-1 저해제와 항체 약물 접합체의 조합
WO2022261301A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2276346B1 (en) * 2008-04-30 2016-11-23 National Health Research Institutes Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JO3474B1 (ar) * 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
FR3037958B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
LT3445767T (lt) 2016-04-22 2020-05-25 Astrazeneca Ab Makrocikliniai mcl-1 inhibitoriai, skirti vėžio gydymui
WO2018015526A1 (en) 2016-07-22 2018-01-25 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
WO2018078064A1 (en) 2016-10-28 2018-05-03 Les Laboratoires Servier Liposomal formulation for use in the treatment of cancer
WO2018126898A1 (zh) 2017-01-05 2018-07-12 河南美泰宝生物制药有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
US20190055264A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. Macrocyclic MCL-1 inhibitors and methods of use
CA3073114A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. Macrocyclic mcl-1 inhibitors and methods of use
WO2019035911A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. MACROCYCLIC INHIBITORS OF MCL-1 AND METHODS OF USE
CN107573360B (zh) 2017-10-27 2019-08-09 都创(上海)医药科技有限公司 一种多靶点小分子化合物s63845的制备方法

Also Published As

Publication number Publication date
US20190144465A1 (en) 2019-05-16
CN111818917A (zh) 2020-10-23
BR112020003180A2 (pt) 2020-09-15
US10676485B2 (en) 2020-06-09
MX2020001717A (es) 2020-10-08
IL272681A (en) 2020-03-31
CA3073112A1 (en) 2019-02-21
RU2020110517A (ru) 2021-09-16
US20230183261A1 (en) 2023-06-15
KR20200041942A (ko) 2020-04-22
UA126586C2 (uk) 2022-11-02
SG10202106345VA (en) 2021-07-29
EP3652184A1 (en) 2020-05-20
EP3652184A4 (en) 2020-05-20
EP3988555A1 (en) 2022-04-27
US20200325153A1 (en) 2020-10-15
ECSP20018703A (es) 2020-04-22
PH12020500327A1 (en) 2020-10-12
CO2020002678A2 (es) 2020-08-10
WO2019035911A1 (en) 2019-02-21
RU2020110517A3 (es) 2022-03-23
UY37843A (es) 2019-03-29
CL2020002943A1 (es) 2021-03-12
JP2020531433A (ja) 2020-11-05
SG11202001182QA (en) 2020-03-30
AU2018316620A1 (en) 2020-03-12
TW201920194A (zh) 2019-06-01
CL2020000363A1 (es) 2020-06-12

Similar Documents

Publication Publication Date Title
PH12020500327A1 (en) Macrocyclic mcl-1 inhibitors and methods of use
WO2019035914A8 (en) Macrocyclic mcl-1 inhibitors and methods of use
PH12018501920B1 (en) Bromodomain inhibitors
MX2020001719A (es) Inhibidores macrocíclicos de mcl-1 y metodos de uso.
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
PH12015502852A1 (en) Bromodomain inhibitor
PH12015502004A1 (en) Tetracyclic bromodomain inhibitors
PH12016501750A1 (en) Human plasma kallikrein inhibitors
JO3474B1 (ar) مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
EA033689B9 (ru) Ингибиторы g12c kras
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MX2015012005A (es) Inhibidores de bromodominio.
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
PH12014501469A1 (en) Bromodomain inhibitors
MX2016007440A (es) Inhibidores del bromodominio.
MX2024009886A (es) Derivados de quinolina como inhibidores de integrina alfa4beta7.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2019004375A (es) Inhibidores de bromodominios.
MX2019004187A (es) Inhibidores de bromodominios.
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
MX2017002627A (es) Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2017002747A (es) Derivados de polieteres macrociclicos de n-aril-triciclopirimidin- 2-amino como inhibidores de ftl3 y jak.